SVB Wealth LLC Trims Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

SVB Wealth LLC reduced its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 9.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 12,235 shares of the company’s stock after selling 1,326 shares during the period. SVB Wealth LLC’s holdings in Takeda Pharmaceutical were worth $175,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in TAK. Simplicity Solutions LLC raised its stake in Takeda Pharmaceutical by 13.1% during the 4th quarter. Simplicity Solutions LLC now owns 241,462 shares of the company’s stock valued at $3,446,000 after acquiring an additional 27,947 shares during the last quarter. NewEdge Wealth LLC raised its stake in Takeda Pharmaceutical by 2.0% during the 4th quarter. NewEdge Wealth LLC now owns 64,920 shares of the company’s stock valued at $926,000 after acquiring an additional 1,290 shares during the last quarter. Bleakley Financial Group LLC raised its stake in Takeda Pharmaceutical by 13.5% during the 4th quarter. Bleakley Financial Group LLC now owns 242,353 shares of the company’s stock valued at $3,458,000 after acquiring an additional 28,838 shares during the last quarter. Advisors Preferred LLC purchased a new stake in Takeda Pharmaceutical during the 4th quarter valued at approximately $201,000. Finally, XY Capital Ltd raised its stake in Takeda Pharmaceutical by 432.5% during the 4th quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock valued at $10,919,000 after acquiring an additional 621,440 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Up 0.2 %

TAK opened at $13.39 on Wednesday. The business has a 50 day moving average price of $14.14 and a two-hundred day moving average price of $14.23. The company has a quick ratio of 0.55, a current ratio of 1.06 and a debt-to-equity ratio of 0.64. The company has a market cap of $42.36 billion, a PE ratio of 20.28, a P/E/G ratio of 3.78 and a beta of 0.53. Takeda Pharmaceutical Company Limited has a 52 week low of $13.11 and a 52 week high of $17.11.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, February 1st. The company reported $0.51 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. The company had revenue of $7.52 billion for the quarter. As a group, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.